Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

Volumn 113, Issue 2, 2012, Pages 234-238

  Nicolatou Galitis, Ourania ^a   Migkou, Magdalini ^b   Psyrri, Amanda ^b   Bamias, Aristotle ^b   Pectasides, Dimitrios ^b   Economopoulos, Theofanis ^b   Raber Durlacher, Judith E ^c   Dimitriadis, George ^b   Dimopoulos, Meletios A ^b  

^a Rhinology Unit and Smell Clinic   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862535407     PISSN: 22124403     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2011.08.024     Document Type: Article

References (33)

1. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29:1338-53. (Pubitemid 47348120)
2. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1:S41-54.
3. Kontovinis LF, Papazisis KT, Touplikioti P, Andreadis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009;9:82, online.
4. Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest 2010:1-9, Online.
5. Mignogna MD, Fortuna G, Leuci S, Pollio A, Ruoppo E. Sunitinib adverse event: oral bullous and lichenoid mucositis. Ann Pharmacother 2009;43:546-7.
6. Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate- related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:463-9.
7. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009;44:173-5.
8. Koch FP, Walter C, Hansen T, Jäger E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 2011;15:63-6.
9. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. (Pubitemid 46211499)
10. Ruggiero S, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrota B, et al. Position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. J Oral Maxillofac Surg 2009;67:S(5):2-12.
11. Migliorati CA, Woo SB, Hewson I, Barasch A, Elting LS, Spijkervet FK, et al. A systematic review of bisphosphonate osteonecrosis (BON) in cancer. Support Care Cancer 2010;18:1099-106.
12. Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis M-C, et al. Osteonecrosis of the jaw (BRONJ) in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, Epub ahead of print 2011, May 30.
13. Murayama Y, Kurihara H, Nagai A, Dompkowski D, Van Dyke TE. Acute necrotizing ulcerative gingivitis: risk factors involving host defense mechanisms. Periodontol 2000;6:116-24.
14. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010;48:221-3.
15. Brown JE, Barrios CE, Diel IJ, Facon T, Fizazi K, Ibrahim T, et al. Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. Bone 2011;48:S18-9.
16. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G III, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. JCO 2008;26:4037-8.
17. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab- associated osteonecrosis of the jaw. Ann Oncol 2008;19:2091-2.
18. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11.
19. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer with anti-angiogenic agents. Cancer Invest 2009;27: 221-6, online.
20. Ayllon J, Vacher-Launay V, Medioni J, Cros C, Spano JP, Oudard S. Ostenocrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 2009;20:600-1.
21. Yarom N, Elad S, Madrid C, Migliorati CA. Osteonecrosis of the jaws induced by drugs other than bisphosphonates-a call to update terminology in light of new data. Oral Oncol 2010;46: e1.
22. Helsloot RS, van den Berg T, Frank MH, Everts V. Bisphosphonate related osteonecrosis of the jaw: a literature review and a new hypothesis. Int J Oral Res 2011;2:e3. Available at: http:// www.ijoronline.com/article.php?article- 2011%3A2%3Be3 (Accessed July 20, 2011).
23. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinba S, et al. Inhibition of oral mucosal cell wound healing by bisphopshonates. J Oral Maxillofac Surg 2008;66:839-47. (Pubitemid 351522817)
24. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67:61-70.
25. Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T. Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 2010;14:35-41.
26. Pazianas M. Osteoneocrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011;103:1-9.
27. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marmé D. Migration of human monocytes in response to endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43. (Pubitemid 26115364)
28. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001;97:785-91. (Pubitemid 32113414)
29. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zolendronic acid. Ann Oncol 2009;20:117-20.
30. Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, Sotiropoulou- Lontou A, Dardoufas K, Polychronopoulou A, et al. Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer 2006, a;14:753-62. (Pubitemid 43886917)
31. Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, Dardoufas K, Kouloulias V, Kyprianou K, et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer 2006, b;14:44-51. (Pubitemid 43119596)
32. Soga Y, Sugiura Y, Takahashi K, Nishimoto H, Maeda Y, Tanimoto M, et al. Progress of oral care and reduction of oral mucositis-a pilot study in a hematopoietic stem cell transplantation ward. Support Care Cancer 2011;19:303-7.
33. Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lontou A, Dardoufas K, Polychronopoulou A, Athanassiadou P, et al. Oral mucositis, pain and xerostomia in 135 head and neck cancer patients receiving radiotherapy with or without chemotherapy. Open Cancer J 2011;4:7-17.